A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Launched by M.D. ANDERSON CANCER CENTER · Feb 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique for breast cancer using a radioactive agent called [18F]FluorThanatrace. This agent is injected into the body and helps doctors see how the cancer behaves during a PET/CT scan, which combines two types of imaging to provide detailed pictures of the body. The goal is to improve the accuracy of imaging in patients who are scheduled for a biopsy or surgery for breast cancer. By seeing how certain enzymes related to cancer growth are active, doctors hope to better understand the disease and tailor treatment accordingly.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of primary breast cancer with a tumor that is at least 1.0 cm in size. They should also be candidates for surgery to remove the cancer. Participants will be informed about the study and must give their consent before joining. It's important to note that pregnant or breastfeeding women cannot take part in this study. If you are eligible and decide to join, you can expect to undergo the PET/CT scans as part of your regular care, helping researchers learn more about this new imaging technique.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants will be \>= 18 years of age
• • Known primary breast cancer. For subjects with primary breast cancer we will target lesion size of 1.0 cm or greater on at least one type of standard clinical imaging (e.g. mammogram, ultrasound, breast magnetic resonance imaging \[MRI\])
• • A candidate for primary breast surgery (mastectomy or lumpectomy)
• • Participants must be informed of the investigational nature of this study and provide written informed consent, in accordance with institutional and federal guidelines prior to study-specific procedures
• Exclusion Criteria:
• • Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to injection of FTT
• • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• • Current or prior therapy for the primary breast cancer
• • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study